A new animal model of postsurgical bowel inflammation and fibrosis: The effect of commensal microflora

Gut

Volumn 58, Issue 8, 2009, Pages 1104-1112

  Rigby, R J ^a   Hunt, M R ^a   Scull, B P ^a   Simmons, J G ^a   Speck, K E ^b   Helmrath, M A ^b   Lund, P K ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ANASTOMOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; ENTERITIS; EXPERIMENTAL MODEL; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; INTESTINAL FIBROSIS; INTESTINE FLORA; INTESTINE RESECTION; MOUSE; NONHUMAN; POSTOPERATIVE INFLAMMATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WILD TYPE;

ANASTOMOSIS, SURGICAL; ANIMALS; CECUM; COLLAGEN; CROHN DISEASE; DISEASE MODELS, ANIMAL; FIBROSIS; GENETIC PREDISPOSITION TO DISEASE; ILEUM; INTERLEUKIN-10; INTESTINE, SMALL; MICE; MICE, KNOCKOUT; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 67650239557     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.157636     Document Type: Article

References (47)

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
2. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(Suppl 1):S3-9.
3. Theiss AL, Fruchtman S, Lund PK. Growth factors in inflammatory bowel disease: the actions and interactions of growth hormone and insulin-like growth factor-I. Inflamm Bowel Dis 2004;10:871-80.
4. Zimmermann EM, Lund PK. Fibrogenesis. In: Sartor RB, Sandborn W, eds. Kirsner's inflammatory bowel disease. 6th edn. Philadelphia: WB Saunders Co., 2004;219-29.
5. Fichera A, Lovadina S, Rubin M, et al. Patterns and operative treatment of recurrent Crohn's disease: a prospective longitudinal study. Surgery 2006;140:649-54.
6. Penner RM, Madsen KL, Fedorak RN. Postoperative Crohn's disease. Inflamm Bowel Dis 2005;11:765-77.
7. Froehlich F, Juillerat P, Felley C, et al. Treatment of postoperative Crohn's disease. Digestion 2005;71:49-53.
8. Froehlich F, Juillerat P, Mottet C, et al. Obstructive fibrostenotic Crohn's disease. Digestion 2005;71:29-30.
9. Sorrentino D, Avellini C, Beltrami CA, et al. Selective effect of infliximab on the inflammatory component of a colonic stricture in Crohn's disease. Int J Colorectal Dis 2006;21:276-81.
10. Thompson JS, DiBaise JK, Iyer KR, et al. Postoperative short bowel syndrome. J Am Coll Surg 2005;201:85-9.
11. Elson CO, Cong Y, McCracken VJ, et al. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 2005;206:260- 76.
12. Sartor RB. Role of commensal enteric bacteria in the pathogenesis of immune-mediated intestinal inflammation: lessons from animal models and implications for translational research. J Pediatr Gastroenterol Nutr 2005;40(Suppl 1):S30-1.
13. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577-94.
14. Isaacs KL, Sartor RB. Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin North Am 2004;33:335-45, x.
15. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004;126:1620-33.
16. Thukral C, Travassos WJ, Peppercorn MA. The role of antibiotics in inflammatory bowel disease. Curr Treat Options Gastroenterol 2005;8:223-8.
17. Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;23:1117-25.
18. Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005;128:856-61.
19. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
20. Elliott PR, Moore GT, Bell SJ, et al. Severe recurrent Crohn's disease of the ileocolonic anastomosis disappearing completely with antibacterial therapy. Gut 2005;54:1818-9.
21. Neut C, Bulois P, Desreumaux P, et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 2002;97:939-46.
22. van Tol EA, Holt L, Li FL, et al. Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibroblasts. Am J Physiol Gastrointest Liver Physiol 1999;277:G245-55.
23. Byrne FR, Viney JL. Mouse models of inflammatory bowel disease. Curr Opin Drug Discov Dev 2006;9:207-17.
24. Hoentjen F, Harmsen HJ, Braat H, et al. Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut 2003;52:1721-7.
25. Kim SC, Tonkonogy SL, Albright CA, et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 2005;128:891- 906.
26. Dekaney CM, Fong JJ, Rigby RJ, et al. Expansion of intestinal stem cells associated with long-term adaptation following ileocecal resection in mice. Am J Physiol Gastrointest Liver Physiol 2007;293:G1013-22.
27. Helmrath MA, Shin CE, Erwin CR, et al. Epidermal growth factor upregulates the expression of its own intestinal receptor after small bowel resection. J Pediatr Surg 1998;33:229-34.
28. Theiss AL, Fuller CR, Simmons JG, et al. Growth hormone reduces the severity of fibrosis associated with chronic intestinal inflammation. Gastroenterology 2005;129:204-19.
29. Sydora BC, Tavernini MM, Wessler A, et al. Lack of interleukin-10 leads to intestinal inflammation, independent of the time at which luminal microbial colonization occurs. Inflamm Bowel Dis 2003;9:87-97.
30. Colombel JF, Watson AJ, Neurath MF. The 10 remaining mysteries of inflammatory bowel disease. Gut 2008;57:429-33.
31. Sorrentino D. Role of biologics and other therapies in stricturing Crohn's disease: what have we learnt so far? Digestion 2008;77:38-47.
32. Isaacs KL, Lewis JD, Sandborn WJ, et al. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 2005;11(Suppl 1):S3-12.
33. Korzenik JR, Podolsky DK. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 2006;5:197-209.
34. Floch MH, Madsen KK, Jenkins DJ, et al. Recommendations for probiotic use. J Clin Gastroenterol 2006;40:275-8.
35. Lepage P, Seksik P, Sutren M, et al. Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm Bowel Dis 2005;11:473-80.
36. Marteau P, Lepage P, Mangin I, et al. Review article: gut flora and inflammatory bowel disease. Aliment Pharmacol Ther 2004;20(Suppl 4):18-23.
37. Paton AW, Morona R, Paton JC. Designer probiotics for prevention of enteric infections. Nat Rev Microbiol 2006;4:193-200.
38. Rioux KP, Fedorak RN. Probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2006;40:260-3.
39. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-9.
40. Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004;4:5.
41. Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006;55:842-7.
42. Meier R, Steuerwald M. Place of probiotics. Curr Opin Crit Care 2005;11:318-25.
43. Kosiewicz MM, Nast CC, Krishnan A, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 2001;107:695-702.
44. Matsumoto S, Okabe Y, Setoyama H, et al. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 1998;43:71-8.
45. Kontoyiannis D, Boulougouris G, Manoloukos M, et al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 2002;196:1563-74.
46. Crawford NP, Colliver DW, Eichenberger MR, et al. CARD15 genotype-phenotype relationships in a small inflammatory bowel disease population with severe disease affection status. Dig Dis Sci 2007;52:2716-24.
47. Brand S, Hofbauer K, Dambacher J, et al. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease phenotype. Am J Gastroenterol 2006;101:99-106.